Paradromics completed the first surgical implantation of its Connexus brain-computer interface in the FDA-approved Connect-One feasibility study at University of Michigan Health. The study is among the first to target speech restoration and builds on a temporary implant that the same surgical team placed during epilepsy research in 2025. It is the first chronic Connexus implant since Paradromics secured its IDE in November 2025.